Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy (SABAL)

Aalborg University

Status: Completed

Conditions: Asthma; Quality of Life; Effects of Immunotherapy; Rhino-Conjunctivitis; Hypersensitivity

Study type: Observational

Funder types: Other

Identifiers

NCT01486498

SABAL

Details and patient eligibility

About

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Enrollment: 571 patients

Sex: All

Ages: 16+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults (> 16 years) and allergic to grass pollen and/or house dust mites.

Exclusion criteria

• Allergic patients who had been immunotherapy treated before.